Overview Performance Dividends Peer Group Options

(BDX) Becton Dickinson - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0758871091

BDX: Medical, Devices, Equipment, Diagnostic, Supplies, Systems

Okay, so Ive got this task where I need to rephrase a description of Becton Dickinson and Company, also known as BD, which is listed on the NYSE under the ticker BDX. The user wants it to be written in the style of Naval Ravikant, who is known for his clear, concise, and insightful thoughts on investing and business. First, I need to understand the original description provided. Its quite detailed, breaking down the company into its three segments: BD Medical, BD Life Sciences, and BD Interventional. Each segment has its own set of products and services. The user also provided some financial metrics and category information, like market cap, P/E ratios, etc. The user wants me to add more details from my own knowledge, so I should think about what else is important for investors and fund managers. BD is a major player in the medical technology sector. They have a long history, founded in 1897, so thats over 125 years in operation. Their products are essential in healthcare, which makes them a stable investment, perhaps even a defensive stock since healthcare needs are consistent regardless of economic cycles. I should also consider their market position. BD is a large-cap company with a market cap of over $66 billion. Their P/E ratio is a bit high at 38, which might indicate that the market expects strong future growth. The forward P/E is lower, around 16, which could mean that analysts expect some deceleration but still solid growth. The P/S ratio is 3.36, which is moderate, indicating that the company is generating decent revenue relative to its market value. BD operates in three main segments. BD Medical probably deals with all the basic medical supplies that hospitals and clinics use daily. Things like syringes, needles, IV catheters, etc. These are high-volume, maybe lower-margin products but essential for healthcare operations. BD Life Sciences seems more focused on diagnostics and research, which could have higher margins and growth potential, especially with trends towards personalized medicine and genetic testing. BD Interventional would be more involved in surgical products and devices, which might have higher margins but could also be subject to more regulatory scrutiny and competition. I should also think about their global presence. BD operates worldwide, which means they have exposure to both developed and emerging markets. This can be a double-edged sword. Emerging markets might offer growth opportunities, but they come with their own set of challenges like currency fluctuations and varying regulatory environments. Another point is their commitment to innovation. As a company with a long history, they must invest in R&D to stay ahead. Their products in areas like molecular testing and gene expression analysis suggest they are keeping up with technological advancements. For investors, its important to note that BD is a diversified company. This diversification can reduce risk because theyre not overly dependent on a single product line or market segment. However, each segment has its own challenges. For example, the medical segment might face pricing pressures from commoditized products, while the life sciences and interventional segments might be more susceptible to technological changes and competition. I should also consider their financial health. With a market cap of over $66 billion, they have significant resources to invest in growth areas, possibly through acquisitions or organic R&D. Their AUM isnt mentioned, but for investors, the P/E ratio is a key metric to watch. A high P/E could mean the market is pricing in future growth, so its important to assess whether BD can meet those expectations. I might also think about their customer base. BD sells to a wide range of customers, from hospitals and clinics to research institutions. This diversification in customer base can provide stability. However, it also means they must navigate different sales channels and customer needs, which can be complex. In terms of risks, as a medical device company, BD is subject to stringent regulations. Any regulatory changes or issues could impact their ability to bring products to market or require significant compliance costs. Additionally, competition is a factor. Companies like Johnson & Johnson, Medtronic, and others operate in similar spaces, so BD needs to maintain a competitive edge through innovation and customer relationships. I should also touch on their supply chain. Medical products often have complex supply chains, especially with global operations. Any disruptions, like those seen during the COVID-19 pandemic, could affect their ability to meet demand and might impact their financials. ESG factors are also important for modern investors. BD, being in healthcare, likely has a positive impact on society, which is a plus. They might also have strong governance and sustainability practices, which are important for long-term value creation. Putting this all together, I need to structure the information in a way thats engaging and informative, written in Naval Ravikants style. That means being clear, concise, and insightful, avoiding fluff and focusing on key points that matter to investors and fund managers. I should start with a general overview, then dive into each segment, highlighting their importance and growth potential. Then,

Additional Sources for BDX Stock

News: Wall Street Journal Benzinga Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

BDX Stock Overview

Market Cap in USD 64,548m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Health Care Equipment
IPO / Inception 1987-01-01

BDX Stock Ratings

Growth 5y 6.05%
Fundamental 22.8%
Dividend 52.8%
Rel. Strength Industry -7.81
Analysts 4.33/5
Fair Price Momentum 212.55 USD
Fair Price DCF 236.27 USD

BDX Dividends

Dividend Yield 12m 1.69%
Yield on Cost 5y 1.71%
Annual Growth 5y 4.50%
Payout Consistency 81.1%

BDX Growth Ratios

Growth Correlation 3m 66.6%
Growth Correlation 12m -17.6%
Growth Correlation 5y 31.8%
CAGR 5y 0.01%
CAGR/Max DD 5y 0.00
Sharpe Ratio 12m -0.40
Alpha -11.61
Beta 0.15
Volatility 19.43%
Current Volume 1920.6k
Average Volume 20d 2131.3k
What is the price of BDX stocks?
As of February 23, 2025, the stock is trading at USD 227.43 with a total of 1,920,647 shares traded.
Over the past week, the price has changed by +1.17%, over one month by -5.38%, over three months by +1.36% and over the past year by -5.72%.
Is Becton Dickinson a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Becton Dickinson is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 22.75 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BDX as of February 2025 is 212.55. This means that BDX is currently overvalued and has a potential downside of -6.54%.
Is BDX a buy, sell or hold?
Becton Dickinson has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy BDX.
  • Strong Buy: 9
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecast for BDX stock price target?
According to ValueRays Forecast Model, BDX Becton Dickinson will be worth about 230.5 in February 2026. The stock is currently trading at 227.43. This means that the stock has a potential upside of +1.34%.
Issuer Forecast Upside
Wallstreet Target Price 276.7 21.6%
Analysts Target Price 278.8 22.6%
ValueRay Target Price 230.5 1.3%